RB1 and breast carcinoma: Moreover, about 4.7% of HR+/HER2– breast cancer patients exhibit Rb mutations (O’Leary et al., 2018; Wander et al., 2020), making CDK4/6i treatment unlikely to be effective, thus making its continuation inadvisable in these cases.